Prompt treatment with therapeutic antiviral neuraminidase (NA) inhibitors can lower influenza morbidity, but these drugs have a limited therapeutic window and are subject to sporadic resistance.1–3 Active antiviral immunization with prophylactic influenza vaccines has remarkably lowered seasonal influenza morbidity and mortality at the population level. The gene discussed is XK; the disease is influenza.